Search results
Medicare Drug Price Negotiation; Diagnostic Errors
MedPage Today· 3 days agoTTHealthWatch is a weekly podcast from Texas Tech. This week's topics include Medicare negotiation on drugs and a loophole, neomycin for preventing...
Opinion | Narcan May Have Moved Over-the-Counter, but It’s Still Underutilized
MedPage Today· 6 days agoThis is just one of the commercials you might have seen or heard for over-the-counter (OTC) naloxone...
Tree pollen hitting a peak for area allergy sufferers
Dayton Daily News· 3 days agoTree pollen is very high right now, data from the Regional Air Pollution Control Agency shows, and...
ARS Pharma submits response to EMA for neffy approval By Investing.com
Investing.com· 6 days agoARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has submitted its response to the European Medicines...
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 8, 2024
Digital Journal· 6 days agoCompany Information Amphastar is a bio-pharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable ...
Why AMD Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Wednesday's Mid-Day...
Benzinga· 5 days agoShares of Advanced Micro Devices, Inc. AMD fell sharply during Wednesday's session as the company...
Small Business - Shelby County Reporter | Shelby County Reporter
The Shelby County Reporter· 3 days agoPhase 2b clinical trial of GH001 in patients with treatment-resistant depression on track for expected completion of double-blind phase in Q3 2024 and of 6-month open-label extension phase in Q1 2025Phase 2a clinical trial of GH001 in postpartum
Why Pinterest Shares Are Trading Higher By 17%; Here Are 20 Stocks Moving Premarket - Pinterest...
Benzinga· 5 days agoShares of Pinterest, Inc PINS rose sharply in today's pre-market trading following strong...
MPM BioImpact-owned Reunion raises $103M, one of the largest rounds for a psychedelic biotech
FierceBiotech· 4 days agoIt’s taken decades for psychedelics to regain clinical and regulatory relevance. Reunion Neuroscience has cashed in on a $103 million series A, building on the promise of a phase 2-stage psychedelic ...